Related Experiment Video
Updated: Feb 9, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Pulmonary Arterial Hypertension: Iron Matters
Latha Ramakrishnan1, Sofia L Pedersen1, Quezia K Toe1
1Cardiorespiratory Interface - Vascular Biology, The National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom.
Disrupted iron regulation is linked to pulmonary artery hypertension (PAH). Restoring iron balance may offer new therapeutic options for PAH patients.
Area of Science:
- Biochemistry
- Physiology
- Pathology
Background:
- Iron and oxygen interactions are vital for aerobic life, requiring tight homeostatic regulation.
- Loss of iron control can lead to disease processes.
- Emerging evidence suggests a link between disrupted iron homeostasis and pulmonary artery hypertension (PAH).
Purpose of the Study:
- To review human iron regulation.
- To describe pulmonary artery hypertension (PAH) classifications.
- To discuss the role of disrupted iron homeostasis in PAH subtypes.
Main Methods:
- Literature review of iron regulation in humans.
- Review of PAH classifications.
- Analysis of emerging research on iron homeostasis and PAH.
Main Results:
- Iron homeostasis is critical for preventing adverse health events.
- Pulmonary artery hypertension (PAH) is a complex disease with various classifications.
- Disrupted iron homeostasis, including hemoglobin decompartmentalization, is implicated in several PAH subtypes.
Conclusions:
- Iron dysregulation may contribute to the development and progression of PAH.
- Understanding the role of iron in PAH opens avenues for novel therapeutic strategies.
- Restoring iron balance presents a potential treatment approach for pulmonary artery hypertension (PAH).
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

